Literature DB >> 25998931

Hepatitis B virus upregulates the expression of kinesin family member 4A.

Cheng-Liang Zhu1, Duo-Zhi Cheng2, Fang Liu3, Xiao-Hong Yan3, Kai-Lang Wu3, Fu-Bing Wang4, Xing-Hui Liu5.   

Abstract

Hepatitis B virus (HBV) infection is one of the major causes of hepatocellular carcinoma (HCC). Kinesin family member 4A (KIF4A) is a microtubule‑based motor protein, which is upregulated in cervical and lung cancer. However, the expression of KIF4A in HBV‑associated HCC, and the effect of HBV on the expression of KIF4A remain to be elucidated. In the present study, the expression profiles of KIF4A were examined in cancerous tissues and paracancerous tissues from patients with HCC, who presented with histories of chronic HBV infection, and the role of HBV in the induction of the expression of KIF4A was investigated. HepG2 cells were transfected with the pHBV1.3, HBV infectious clone and a construct, which contained the luciferase gene under the control of the KIF4A gene promoter. The results demonstrated that the expression of KIF4A was significantly higher in the HCC tissues than in the paracancerous tissues. HBV activated the KIF4A gene promoter and upregulated the mRNA and protein expression of KIF4A. Furthermore, activation of the gene expression of KIF4A increased in a pHBV1.3 concentration‑dependent manner. These results provide novel insights into the understanding of HCC oncogenesis caused by HBV.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998931     DOI: 10.3892/mmr.2015.3792

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Hepatitis B virus inhibits the expression of complement C3 and C4, in vitro and in vivo.

Authors:  Chengliang Zhu; Hui Song; Fengxia Xu; Wei Yi; Fang Liu; Xinghui Liu
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

2.  Kinesin KIF4A is associated with chemotherapeutic drug resistance by regulating intracellular trafficking of lung resistance-related protein.

Authors:  Li-Na Pan; Yuan Zhang; Chang-Jun Zhu; Zhi-Xiong Dong
Journal:  J Zhejiang Univ Sci B       Date:  2017 Dec.       Impact factor: 3.066

3.  Upregulate KIF4A Enhances Proliferation, Invasion of Hepatocellular Carcinoma and Indicates poor prognosis Across Human Cancer Types.

Authors:  Guojun Hou; Chuanpeng Dong; Zihui Dong; Gang Liu; Huilin Xu; Lei Chen; Lei Liu; Hongyang Wang; Weiping Zhou
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

4.  HBV Upregulates CtBP2 Expression via the X Gene.

Authors:  Xinghui Liu; Chengliang Zhu; Jie Li; Fengxia Xu; Gang Huang; Limin Xu; Binghong Zhang
Journal:  Biomed Res Int       Date:  2018-07-31       Impact factor: 3.411

5.  FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression.

Authors:  Guohui Hu; Zhengwei Yan; Cheng Zhang; Minzhang Cheng; Yehong Yan; Yiting Wang; Libin Deng; Quqin Lu; Shiwen Luo
Journal:  J Exp Clin Cancer Res       Date:  2019-05-09

6.  Identification of Key Biomarkers and Pathways in Small-Cell Lung Cancer Using Biological Analysis.

Authors:  Huanqing Liu; Tingting Li; Xunda Ye; Jun Lyu
Journal:  Biomed Res Int       Date:  2021-10-19       Impact factor: 3.411

7.  The kinesin KIF4 mediates HBV/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro.

Authors:  Sameh A Gad; Masaya Sugiyama; Masataka Tsuge; Kosho Wakae; Kento Fukano; Mizuki Oshima; Camille Sureau; Noriyuki Watanabe; Takanobu Kato; Asako Murayama; Yingfang Li; Ikuo Shoji; Kunitada Shimotohno; Kazuaki Chayama; Masamichi Muramatsu; Takaji Wakita; Tomoyoshi Nozaki; Hussein H Aly
Journal:  PLoS Pathog       Date:  2022-03-21       Impact factor: 6.823

8.  Upregulation of kinesin family member 4A enhanced cell proliferation via activation of Akt signaling and predicted a poor prognosis in hepatocellular carcinoma.

Authors:  Yanlin Huang; Hongbo Wang; Yifan Lian; Xiaojuan Wu; Liang Zhou; Jialiang Wang; Meihai Deng; Yuehua Huang
Journal:  Cell Death Dis       Date:  2018-02-02       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.